Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug;26(8):3471-3474.
doi: 10.1111/dom.15639. Epub 2024 May 3.

A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study)

Akihiro Takahashi  1 , Hiroshi Nomoto  1 , Kinnosuke Onishi  1 , Satoru Manda  1 , Aika Miya  1 , Hiraku Kameda  1 , Akinobu Nakamura  1 , Tatsuya Atsumi  1
Affiliations
Randomized Controlled Trial

A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study)

Akihiro Takahashi et al. Diabetes Obes Metab. 2024 Aug.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol. 2021;20:9.
    1. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
    1. Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;2022(45):2753‐2786.
    1. Kanto K, Ito H, Noso S, et al. Effects of dosage and dosing frequency on the efficacy and safety of high‐dose metformin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;9:587‐593.
    1. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:852‐858.

MeSH terms

LinkOut - more resources